Related Experiment Video
Updated: May 6, 2026
08:33
Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research
Published on: January 5, 2024
2.0K
Anticonvulsants for fibromyalgia.
Nurcan Üçeyler1, Claudia Sommer, Brian Walitt
1Department of Neurology, University of Würzburg, Würzburg, Germany, 97080.
The Cochrane Database of Systematic Reviews
|October 17, 2013
Summary
Anticonvulsants like pregabalin offer a small benefit for fibromyalgia pain and sleep issues, but do not significantly reduce fatigue. Increased adverse events, including dizziness, were noted with pregabalin use.
Area of Science:
- Neurology
- Pharmacology
- Rheumatology
Background:
- Fibromyalgia (FM) is a chronic condition causing widespread pain, fatigue, and sleep disturbances, significantly impacting quality of life.
- Current drug therapies aim to alleviate symptoms and improve health-related quality of life (HRQoL).
- Anticonvulsants are frequently prescribed for chronic pain management.
Purpose of the Study:
- To evaluate the efficacy and safety of anticonvulsant medications for treating fibromyalgia symptoms.
- To assess the benefits and harms of these drugs in FM patients.
Main Methods:
- Systematic review of randomized controlled trials (RCTs) involving anticonvulsants for FM treatment.
- Searched multiple databases (CENTRAL, MEDLINE, PsycINFO, SCOPUS) and clinical trial registries.
- Included eight RCTs (pregabalin, gabapentin, lacosamide, levetiracetam); data extracted and risk of bias assessed.
Main Results:
- Sufficient evidence supports pregabalin's efficacy in reducing pain and improving overall well-being.
- Pregabalin showed a small benefit for sleep problems but did not substantially reduce fatigue.
- Higher dropout rates due to adverse events were observed with pregabalin, with dizziness being a common side effect.
Conclusions:
- Pregabalin offers modest benefits for fibromyalgia pain and sleep, but its impact on fatigue is limited.
- Increased adverse events and dizziness necessitate careful consideration of pregabalin use.
- Evidence for other anticonvulsants (gabapentin, lacosamide, levetiracetam) in FM treatment remains insufficient.
Related Concept Videos
01:14Antiepileptic Drugs: Glutamate Antagonists
1.3K
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
1.3K
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
1.8K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.8K
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
1.2K
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.2K
01:09Peripherally and Centrally Acting Muscle Relaxants: A Comparison
5.7K
Skeletal muscle relaxants can target the central nervous system [CNS] to reduce muscle tension or act directly at the neuromuscular junction to induce temporary paralysis. These two classes of muscle relaxants are called centrally acting muscle relaxants and peripherally acting muscle relaxants. They differ in their action, mechanism, administration route, and clinical uses.
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic...
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic...
5.7K
01:24Centrally Acting Muscle Relaxants: Therapeutic Uses
1.7K
Centrally acting muscle relaxants reduce muscle tone and tension by interfering with the postsynaptic reflexes in the central nervous system.
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...
1.7K
01:29Spasmolytic Agents: Chemical Classification
1.5K
Spasmolytic agents are drugs used to alleviate muscle spasms and spasticity. They can be categorized into different chemical groups based on their mechanisms of action. Centrally acting spasmolytics primarily affect the spinal cord, while others directly target skeletal muscle cells.
A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also...
A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also...
1.5K